BrightEdge

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Modifi Biosciences specializes in direct DNA modification and the creation of innovative cancer therapeutics. The company's primary focus is on altering tumor DNA in a way that makes cancer cells irreparable while preserving healthy cells. This distinctive methodology allows researchers to challenge and transform traditional approaches to oncology drug development. By exploiting DNA defects across various cancer types, Modifi Biosciences aims to provide effective treatments that target the underlying genetic issues in tumors, thereby advancing the field of cancer therapeutics.

Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.

Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

Vincere Health Inc. is a health technology company based in Allston, Massachusetts, founded in 2019 at the Harvard Innovation Labs. The company has developed a mobile application aimed at assisting users in quitting smoking and making healthier choices through a combination of behavioral nudges, incentives, and evidence-based interventions. Users can set personal health goals and test their adherence by using an attachable breathalyzer device to track their smoking habits daily. The platform offers immediate financial rewards for users who reduce their smoking and ultimately quit. Additionally, Vincere Health provides personalized coaching and real-time progress tracking to support chronic disease management and promote healthier lifestyle choices, addressing significant healthcare challenges primarily focused on smoking cessation.

Meliora Therapeutics is a biotech startup focused on developing innovative cancer therapies through a machine learning-driven platform. The company aims to identify the true mechanisms of action of oncology medications by utilizing a proprietary prediction atlas that maps drug mechanisms. This approach allows Meliora to streamline the drug development process by reducing the time and costs typically associated with traditional methods. By pinpointing the specific actions of therapeutic molecules, Meliora Therapeutics seeks to enhance the efficacy of cancer treatments and accelerate the delivery of life-saving therapies to patients.

Naveris Inc. is a biotechnology company specializing in the development of sensitive blood tests for early cancer detection, which enhances patient outcomes. Founded in 2017 and based in Waltham, Massachusetts, Naveris offers NavDx, a blood test that identifies human papilloma virus-associated cancers by quantifying tumor-specific DNA fragments released into the bloodstream. The company's innovative biomimetic technology simulates the complexities of human tissues and tumors, facilitating early diagnosis in asymptomatic individuals, real-time monitoring of treatment responses, and the detection of cancer recurrence in patients in remission. Naveris aims to improve oncology clinical trials and precision medicine, ensuring that therapies are effectively matched to individual patients.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.